English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/151031
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorPareja-Galeano, Helios-
dc.contributor.authorSanchis-Gomar, Fabian-
dc.contributor.authorPérez, Laura M.-
dc.contributor.authorEmanuele, Enzo-
dc.contributor.authorLucia, Alejandro-
dc.contributor.authorGálvez, Beatriz G.-
dc.contributor.authorGallardo, M. Esther-
dc.date.accessioned2017-06-07T11:59:50Z-
dc.date.available2017-06-07T11:59:50Z-
dc.date.issued2016-
dc.identifierdoi: 10.1016/j.arr.2016.02.007-
dc.identifiere-issn: 1872-9649-
dc.identifierissn: 1568-1637-
dc.identifier.citationAgeing Research Reviews 27: 37-41 (2016)-
dc.identifier.urihttp://hdl.handle.net/10261/151031-
dc.description.abstractThe main biological hallmarks of the aging process include stem cell exhaustion and cellular senescence. Consequently, research efforts to treat age-related diseases as well as anti-aging therapies in general have recently focused on potential 'reprogramming' regenerative therapies. These new approaches are based on induced pluripotent stem cells (iPSCs), including potential in vivo reprogramming for tissue repair. Another possibility is targeting pathways of cellular senescence, e.g., through modulation of p16INK4a signaling and especially inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Here, we reviewed and discussed these recent developments together with their possible usefulness for future treatments against sarcopenia, a major age-related condition.-
dc.description.sponsorshipThis work was supported by grants from the “Instituto de Salud Carlos III” [Fondo de Investigacion Sanitaria and Regional Development Fund (ERDF/FEDER) funds PI15/00558 to AL and PI15/00484 to MEG]. This study was supported by grants from the Spanish Ministry of Science and Innovation (SAF 2015-67911) to BGG.-
dc.publisherElsevier-
dc.relationMINECO/ICTI2013-2016/SAF2015-67911-R-
dc.relation.isversionofPostprint-
dc.rightsopenAccess-
dc.subjectInduced pluripotent stem cells-
dc.subjectRegenerative medicine-
dc.subjectDOT1L-
dc.subjectIn vivo reprogramming-
dc.subjectSarcopenia-
dc.titleIPSCs-based anti-aging therapies: Recent discoveries and future challenges-
dc.typeartículo-
dc.identifier.doi10.1016/j.arr.2016.02.007-
dc.relation.publisherversionhttps://doi.org/10.1016/j.arr.2016.02.007-
dc.date.updated2017-06-07T11:59:50Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
dc.rights.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.contributor.funderMinisterio de Ciencia e Innovación (España)-
dc.contributor.funderMinisterio de Economía y Competitividad (España)-
dc.contributor.funderInstituto de Salud Carlos III-
dc.relation.csic-
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004837es_ES
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
ipscsbased.pdf423,26 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.